Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI EAFE ETF (IEFA) vs Eli Lilly And Co (LLY) Price & Performance

iShares Core MSCI EAFE ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares Core MSCI EAFE ETF vs Eli Lilly And Co — how do they compare? iShares Core MSCI EAFE ETF trades at $100.86, while Eli Lilly And Co trades at $1,215.81 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals.

IEFALLY
Sector
Broad Market / FactorHealth
52-Week High
$101.09$1.24K
52-Week Low
$84.72$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI EAFE ETF

IEFA trades at $101.28, up 0.75% today, with a bullish technical outlook from moving averages but overbought RSI signals. The ETF focuses on developed international markets excluding the U.S. and Canada, offering diversification and a dividend yield. Recent news highlights its role in defensive portfolio shifts and comparisons with peers like VXUS and SPGM.

Outlook is positive for diversification seekers amid U.S. concentration risks, supported by lower fees and income appeal. Risks include developed-market economic sensitivity and currency fluctuations. Analyst sentiment is generally favorable for long-term exposure.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY